MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alkermes Plc Company Profile (NASDAQ:ALKS)

Consensus Ratings for Alkermes Plc (NASDAQ:ALKS) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $59.80 (49.46% upside)

Analysts' Ratings History for Alkermes Plc (NASDAQ:ALKS)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Evercore ISIInitiated CoverageBuy$59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016Leerink SwannReiterated RatingOutperform$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Morgan StanleyReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$57.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Citigroup Inc.Lower Price TargetNeutral$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2016GuggenheimReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$77.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015BarclaysReiterated RatingBuy$79.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Bank of AmericaSet Price TargetSell$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2015MizuhoBoost Price TargetBuy$72.00 -> $81.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Alkermes Plc (NASDAQ:ALKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2014Q314$0.02$0.03$155.53 million$160.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q314$0.14$0.11$146.91 million$153.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.16$0.39ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.11)$0.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alkermes Plc (NASDAQ:ALKS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Alkermes Plc (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alkermes Plc (NASDAQ:ALKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Alkermes Plc (NASDAQ:ALKS)
DateHeadline
06/24/16 02:24 PMPrice Target Update on Alkermes plc (NASDAQ:ALKS) - Trade Calls
06/23/16 10:11 AMHealthcare Sector Equities Under the Scanner - Alkermes, AMAG Pharma, IDEXX Laboratories, and Aduro BioTech
06/22/16 07:14 AMAlkermes plc (NASDAQ:ALKS) Analyst Rating Consensus - TheFounders Daily
06/21/16 10:21 AMAlkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016 -
06/21/16 07:11 AMAlkermes: Is The Market Missing An Opportunity? - Seeking Alpha
06/20/16 07:38 AMAlkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016 -
06/15/16 07:30 PMWhich way Alkermes plc (NASDAQ:ALKS) earnings may go - iStreetWire
06/14/16 02:24 PMTrend Of Rating Given To Alkermes plc (NASDAQ:ALKS) - Investor Newswire
06/13/16 02:24 PMAnalyst Suggestions Roundup: Alkermes plc (NASDAQ:ALKS), Norwegian Cruise Line Holdings Ltd. (NASDAQ:NCLH) - Beacon Chronicle
06/08/16 03:19 PMALKERMES PLC. Files SEC form 8-K, Other Events -
06/08/16 01:10 PMETF’s with exposure to Alkermes Plc : June 8, 2016 -
06/08/16 10:51 AMEarnings Review: Aon plc (NYSE:AON), Alkermes plc (NASDAQ:ALKS) - Beacon Chronicle
06/07/16 02:25 PMCan Alkermes plc (NASDAQ:ALKS) Meet Analysts Expectations? - Stocks Daily
06/03/16 08:28 PMAlkermes Plc (ALKS) Stock Rating Reaffirmed by Credit Suisse - Let Me Know About This
06/02/16 03:11 PMALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/02/16 11:02 AMEarnings Expectations Overview: Alkermes plc (NASDAQ:ALKS), Amphenol Corporation (NYSE:APH) - Beacon Chronicle - Beacon ChronicleEarnings Expectations Overview: Alkermes plc (NASDAQ:ALKS), Amphenol Corporation (NYSE:APH)Beacon ChronicleLast Trade: The Company closed its last session at $45.84 with the loss of -1.23%. The market capitalization of the company is $6.91 Billion, with the average Volume of 1.41 Million. The stock currently has its 52-Week High range of $80.71 and 52-week ...and more »
06/01/16 03:15 PMAlkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - Alkermes' Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference DUBLIN--(BUSINESS WIRE)--Jun. 1, 2016-- Alkermes plc (NASDAQ: ALKS) announced today that its ...
06/01/16 07:30 AMAlkermes Plc Conference Call to Discuss Data and Study Design from FORWARD-3 and FORWARD-4 Studies of ALKS 5461 scheduled for 8:30 am ET today -
05/31/16 08:24 AMStock Review and Earnings Check on Alkermes plc (NASDAQ:ALKS) - HNN - Stock Review and Earnings Check on Alkermes plc (NASDAQ:ALKS)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Alkermes plc (NASDAQ:ALKS) to ...and more »
05/27/16 06:39 PMHealthcare Stocks Review: Shire plc (NASDAQ:SHPG) , Alkermes plc (NASDAQ:ALKS) - Is stories - Is storiesHealthcare Stocks Review: Shire plc (NASDAQ:SHPG) , Alkermes plc (NASDAQ:ALKS)Is storiesIn most recently trading session on 5/26/2016, Alkermes plc (NASDAQ:ALKS) climbed +1.63% while traded on 1.3 million shares versus it's an average volume of 1.42 million shares. The company recorded the last trade with the price of $44.29. The stock ...and more »
05/27/16 09:45 AMHealthcare Stocks News Review: Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Alkermes Plc(NASDAQ:ALKS) - NYSE Journal (press release) - Healthcare Stocks News Review: Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Alkermes Plc(NASDAQ:ALKS)NYSE Journal (press release)On Thursday, Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR), added 5.48% and closed at $29.26 in the last trading session. The last trading range of the stock ranges between $27.12 and $29.93. Alder BioPharmaceuticals, Inc. (ALDR), ...and more »
05/26/16 11:40 PMAlkermes plc (NASDAQ:ALKS) Costs Of Goods Sold Stands At $138.989 Millions - RealistInvestor.com - Alkermes plc (NASDAQ:ALKS) Costs Of Goods Sold Stands At $138.989 MillionsRealistInvestor.comFor the fiscal ended 2015-12-31, Alkermes plc (NASDAQ:ALKS) comprehensive income was $-3.795 millions and for the quarter ended 2015-12-31, it was $-3.795 millions. Alkermes plc (NASDAQ:ALKS) posted $-227.163 millions on net loss/income for the ...and more »
05/26/16 03:50 PMALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur -
05/26/16 09:59 AMAlkermes plc (NASDAQ:ALKS) Closes At $43.42 - Investor Newswire - Pharmaceutical Business ReviewAlkermes plc (NASDAQ:ALKS) Closes At $43.42Investor NewswireYesterday, the stock of Alkermes plc (NASDAQ:ALKS) closed at $43.42 after opening at $43.91 and registering high of $44.37 and low of $43.03. The last price is $-37.27 off 1-year high of $80.71 and $16.30 away from low of $27.14 during same period.Evercore ISI Group Starts Coverage on Alkermes plc (ALKS) With An Initial Rating Of "Buy"Finance Dailyall 9 news articles »
05/26/16 06:07 AMAlkermes Appoints Nancy Snyderman, M.D., to Board of Directors - [at noodls] - DUBLIN--(BUSINESS WIRE)--May 26, 2016-- Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company's Board of Directors. Dr. Snyderman most recently served ...
05/25/16 12:37 PMAlkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230 - Alkermes Plc (NASDAQ: ALKS) revealed Wednesday that it initiated a phase 1 clinical trial of its immuno-oncology drug candidate, ALKS 4230, which was formerly referred to as RDB 1450, a novel Selective Effector Cell Activator protein designed for targeted interleukin-2 (IL-2) receptor activation. The company expects the initial results from the first stage of the phase 1 trial next year. According to the company, the multi-center phase 1 study is meant to assess the safety, tolerability and immunological-pharmacodynamic effects of ALKS 4230 in the treatment of patients with solid tumors. Alkermes Chief Medical Officer Elliot Ehrich commented ...Full story available on Benzinga.com
05/25/16 09:52 AMTwo Stocks to Monitor: Alkermes plc (NASDAQ:ALKS) , DaVita healthCare Partners Inc. (NYSE:DVA) - Street Updates - Two Stocks to Monitor: Alkermes plc (NASDAQ:ALKS) , DaVita healthCare Partners Inc. (NYSE:DVA)Street UpdatesAlkermes plc (NASDAQ:ALKS) accumulated +1.26%, closing at $43.42 after floating between $42.81 and $44.28. The company has market capitalization of $6.56B. It has twelve month low of $27.14 and twelve month high of $80.71. The recent traded volume ...and more »
05/25/16 09:52 AMAlkermes plc (ALKS) Commences ALKS 4230 Phase 1 - StreetInsider.com - Alkermes plc (ALKS) Commences ALKS 4230 Phase 1StreetInsider.comAlkermes plc (Nasdaq: ALKS) announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA™) protein designed for ...and more »
05/25/16 06:06 AMAlkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 - [at noodls] - - Novel Selective Effector Cell Activator (SECA™) Protein Designed for Targeted IL-2 Receptor Activation to Enhance Tumor-Killing Immune Cells - DUBLIN--(BUSINESS WIRE)--May 25, 2016-- Alkermes plc (NASDAQ: ...
05/25/16 06:01 AM7:01 am Alkermes initiates a phase 1 clinical study of its immuno-oncology drug candidate, ALKS 4230; initial results from the first stage are expected in 2017 -
05/24/16 01:45 PMETF’s with exposure to Alkermes Plc : May 24, 2016 -
05/24/16 10:19 AMEarnings Review and Stock Rundown for Alkermes plc (NASDAQ:ALKS) - Wall Street Hints and News - Earnings Review and Stock Rundown for Alkermes plc (NASDAQ:ALKS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Alkermes plc (NASDAQ:ALKS) to post ...and more »
05/24/16 06:06 AMAlkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting - [at noodls] - - Company to Host Webcast Presentation and Conference Call on Wednesday, June 1 - - Management Will Discuss Data and Study Design Details From FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 ...
05/23/16 11:31 AMHC Sector Latest Updates: Alkermes Plc (NASDAQ:ALKS), Apricus Biosciences Inc (NASDAQ:APRI) - share market updates (press release) - share market updates (press release)HC Sector Latest Updates: Alkermes Plc (NASDAQ:ALKS), Apricus Biosciences Inc (NASDAQ:APRI)share market updates (press release)Shares of Alkermes Plc (NASDAQ:ALKS) ended Friday session in green amid volatile trading. The shares closed up +3.72 points or 9.48% at $42.98 with 2.43 million shares getting traded. Post opening the session at $39.65, the shares hit an intraday low ...and more »
05/22/16 05:50 PMPerformance at a Glance on Alkermes plc (NASDAQ:ALKS) - Wall Street Hints and News - Performance at a Glance on Alkermes plc (NASDAQ:ALKS)Wall Street Hints and NewsWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Alkermes plc (NASDAQ:ALKS)'s stock has performed at various points in its past. Currently, the stock ...and more »
05/20/16 11:29 PMAlkermes Plc (ALKS) Ascent Sends Options Volume to the Moon - Schaeffers Research (blog) - Schaeffers Research (blog)Alkermes Plc (ALKS) Ascent Sends Options Volume to the MoonSchaeffers Research (blog)A number of drug stocks are making moves higher, and biotech Alkermes Plc (NASDAQ:ALKS) is no exception amid unsubstantiated takeover talk. Up 8.4% at $42.55 ahead of next Wednesday's annual shareholder meeting, the stock is seeing call options fly ...Is it Time to Cash in Profits on Alkermes plc (NASDAQ:ALKS)Franklin IndependentHow Many Alkermes Plc (NASDAQ:ALKS)'s Analysts Are Bullish?The PostState Street Corp Modifies Its Holdings in Alkermes plc (ALKS) StockFinance Dailyall 5 news articles »
05/20/16 06:22 PM10 Biggest Mid-Day Gainers For Friday - Alkermes Plc (NASDAQ: ALKS) traded up 8.17 percent after traders passed around speculation of possible sale around $60 per share. Mazor Robotics Ltd - ADR (NASDAQ: MZOR) traded up 7.95 percent, continuing its uptrend after being upgraded on Thursday.
05/20/16 06:22 PMAlkermes Plc (ALKS) Ascent Sends Options Volume to the Moon - A number of drug stocks are making moves higher, and biotech Alkermes Plc (NASDAQ:ALKS) is no exception amid unsubstantiated takeover talk. Up 8.4% at $42.55 ahead of next Wednesday's annual shareholder meeting, the stock is seeing call options fly off the ...
05/19/16 06:24 PMWhy Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics? - ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ ...
05/19/16 09:51 AMCowen & Company Assumes Alkermes Plc to Market Perform - Trade Calls - Cowen & Company Assumes Alkermes Plc to Market PerformTrade CallsBrokerage firm Cowen & Company Assumes its rating on Alkermes Plc(NASDAQ:ALKS). The shares have been rated Market Perform. The rating by Cowen & Company was issued on May 5, 2016. Alkermes Plc (ALKS) made into the market gainers list on ...
05/18/16 10:42 AMAlkermes Plc Ord (NASDAQ:ALKS) Sellers Covered 2.13% of Their Shorts - Wall Street Hints and News - Alkermes Plc Ord (NASDAQ:ALKS) Sellers Covered 2.13% of Their ShortsWall Street Hints and NewsThe stock of Alkermes Plc Ord (NASDAQ:ALKS) registered a decrease of 2.13% in short interest. ALKS's total short interest was 6.32 million shares in May as published by FINRA. Its down 2.13% from 6.46M shares, reported previously. With 1.40 million ...Have a look at Price Moves: Quest Diagnostics Incorporated (NYSE:DGX) , Alkermes plc (NASDAQ:ALKS)Street Updatesall 2 news articles »
05/17/16 11:20 PMHealthcare Movers to Target: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Alkermes plc (NASDAQ:ALKS) - Is stories - Is storiesHealthcare Movers to Target: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Alkermes plc (NASDAQ:ALKS)Is storiesTeva Pharmaceutical Industries Limited (NYSE:TEVA) increased +0.26% to $50.43 while traded 6.66 million shares on 5/16/2016. The stock price negotiated for value between $49.61 to $50.62 in recent trading session. During the past 52 weeks, the stock's ...and more »
05/17/16 11:20 PMBuy Calls Count For Alkermes plc (NASDAQ:ALKS) At 0 - Stocks Daily - Buy Calls Count For Alkermes plc (NASDAQ:ALKS) At 0Stocks DailyZacks line of rating gives scores to firms on a basic 1-5 scale. As per this rating line, a score close to the lower band of 1-2 indicates a Buy, 3 rating calls for Hold while 4 or 5 rating denotes Sell. Most of the research firms have their self ...and more »
05/16/16 11:41 AMInvestors Reviewing Stocks: Alkermes plc (NASDAQ:ALKS) , CTI BioPharma Corp. (NASDAQ:CTIC) - Street Updates - Investors Reviewing Stocks: Alkermes plc (NASDAQ:ALKS) , CTI BioPharma Corp. (NASDAQ:CTIC)Street UpdatesOn 5/13/2016, shares of Alkermes plc (NASDAQ:ALKS) rose +1.22% in trading session and finally closed at $37.45. The company most recent volume stood at 689.48 thousand shares as compared to its average volume of 1.48 million shares. Over the one ...
05/08/16 06:59 PMAfter Last Week What Do Analysts Think Of Alkermes Plc (NASDAQ:ALKS) - Share Trading News - After Last Week What Do Analysts Think Of Alkermes Plc (NASDAQ:ALKS)Share Trading News04/09/2014 – Alkermes plc had its “sell” rating reiterated by analysts at MKM Partners. They now have a USD 35 price target on the stock. The share price of Alkermes plc (NASDAQ:ALKS) was up +0.68% during the last trading session, with a day high of ...Market Analyst Recent Rating Update: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Alkermes plc (NASDAQ:ALKS)WsNews 4investorsall 2 news articles »
05/04/16 06:40 PMNotable Stocks Preview: Alkermes plc (NASDAQ:ALKS) , Cerus Corporation (NASDAQ:CERS) - Street Updates - Notable Stocks Preview: Alkermes plc (NASDAQ:ALKS) , Cerus Corporation (NASDAQ:CERS)Street UpdatesOn 5/3/2016, Alkermes plc (NASDAQ:ALKS) ended trading session lower at $39.20 with -2.87%. The company traded a volume of 1.77 million shares as comparison to average volume of 1.62 million shares. During the 52 –week period, the stock's price ...and more »
05/04/16 04:56 AMAverage Analyst Rating for Alkermes plc (NASDAQ:ALKS) - B.O.D.Y Confidential - Average Analyst Rating for Alkermes plc (NASDAQ:ALKS)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2.04 on Alkermes plc (NASDAQ:ALKS) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 11:22 PMFDA Warns of Rare Impulse Reactions to Abilify Medication -
05/03/16 06:02 PM[$$] FDA Warns of Rare Reactions to Abilify Medication -
05/03/16 09:52 AMAlkermes Plc :ALKS-US: Earnings Analysis: Q1, 2016 By the Numbers -
About Alkermes Plc

Alkermes Plc logoAlkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Company's main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Delivery
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALKS
  • CUSIP: G0176710
Key Metrics:
  • Previous Close: $42.28
  • 50 Day Moving Average: $42.40
  • 200 Day Moving Average: $44.76
  • P/E Ratio: N/A
  • P/E Growth: 6.31
  • Market Cap: $6.03B
  • Current Quarter EPS Consensus Estimate: $-0.29 EPS
Additional Links:
Alkermes Plc (NASDAQ:ALKS) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha